...
首页> 外文期刊>Seminars in Respiratory and Critical Care Medicine >The Microbiome and Emerging Pathogens in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis
【24h】

The Microbiome and Emerging Pathogens in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis

机译:囊性纤维化和非囊性纤维化支气管扩张症中的微生物组和新兴病原体

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Chronic pulmonary sepsis is the predominant cause of morbidity for patients with cystic fibrosis (CF) and non-CF bronchiectasis. Previously it was thought that respiratory infection in these patients was mostly limited to a very small number of typical pathogens; however, in recent years there have been increasing reports of infection with other emerging potential pathogens including Burkholderia, Stenotrophomonas, Achromobacter, Ralstonia, Pandoraea, nontuberculous mycobacteria, and fungal species. Furthermore, culture-independent methodologies have established that the lungs of patients with CF and non-CF bronchiectasis comprise mixed microbiological communities of aerobic and anaerobic bacteria, fungal and viral species, collectively referred to as the lung microbiome. This article addresses the clinical relevance of emerging pathogens and the lung microbiome in CF and non-CF bronchiectasis.
机译:慢性肺败血症是囊性纤维化(CF)和非CF支气管扩张患者发病的主要原因。以前认为这些患者的呼吸道感染大多局限于极少数典型的病原体。然而,近年来,越来越多的报告表明感染了其他新出现的潜在病原体,包括伯克霍尔德氏菌,嗜麦芽窄食单胞菌,无色杆菌,Ralstonia,潘多拉花,非结核分枝杆菌和真菌。此外,不依赖培养物的方法已确定,患有CF和非CF支气管扩张的患者的肺部包括需氧和厌氧细菌,真菌和病毒物种的混合微生物群落,统称为肺微生物组。本文探讨了CF和非CF支气管扩张中新兴病原体和肺微生物组的临床相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号